Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study

Schizophrenia Research

Volumn 149, Issue 1-3, 2013, Pages 21-25

  Ramsey, Timothy L ^a   Liu, Qian ^a   Massey, Bill W ^a   Brennan, Mark D ^a  

^a SureGene LLC   (United States)

Author keywords

CATIE trial; Olanzapine; Pharmacogenomics; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC VESICLE PROTEIN 2C GENE;

CATIE TRIAL; OLANZAPINE; PHARMACOGENOMICS; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84881257528     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.008     Document Type: Article

References (20)

1. Aberg K., Adkins D.E., Liu Y., McClay J.L., Bukszar J., Jia P., Zhao Z., Perkins D., Stroup T.S., Lieberman J.A., Sullivan P.F., Van Den Oord E.J. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012, 12:165-172.
2. Adkins D.E., Aberg K., McClay J.L., Bukszar J., Zhao Z., Jia P., Stroup T.S., Perkins D., McEvoy J.P., Lieberman J.A., Sullivan P.F., Van Den Oord E.J. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 2011, 16:321-332.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125:279-284.
5. Dardou D., Dassesse D., Cuvelier L., Deprez T., De R.M., Schiffmann S.N. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res. 2011, 1367:130-145.
6. Dardou D., Monlezun S., Foerch P., Courade J.P., Cuvelier L., De R.M., Schiffmann S.N. A role for Sv2c in basal ganglia functions. Brain Res. 2013, 1507:61-73.
7. Fijal B.A., Stauffer V.L., Kinon B.J., Conley R.R., Hoffmann V.P., Witte M.M., Zhao F., Houston J.P. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J. Clin. Psychiatry 2012, 73:367-371.
8. Gronborg M., Pavlos N.J., Brunk I., Chua J.J., Munster-Wandowski A., Riedel D., Ahnert-Hilger G., Urlaub H., Jahn R. Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J. Neurosci. 2010, 30:2-12.
9. Guidotti A., Auta J., Davis J.M., Dong E., Grayson D.R., Veldic M., Zhang X., Costa E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005, 180:191-205.
10. Hill-Burns E.M., Singh N., Ganguly P., Hamza T.H., Montimurro J., Kay D.M., Yearout D., Sheehan P., Frodey K., McLear J.A., Feany M.B., Hanes S.D., Wolfgang W.J., Zabetian C.P., Factor S.A., Payami H. A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. Pharmacogenomics J. 2012, (Advance online publication, 2 October 2012). http://dx.doi.org/10.1038/tpj.2012.38.
11. Iezzi M., Theander S., Janz R., Loze C., Wollheim C.B. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J. Cell Sci. 2005, 118:5647-5660.
12. Lavedan C., Licamele L., Volpi S., Hamilton J., Heaton C., Mack K., Lannan R., Thompson A., Wolfgang C.D., Polymeropoulos M.H. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 2009, 14:804-819.
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
14. Liu Q., Jamba M., Patrick C., Padmanabhan S., Brennan M.D. Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics 2012, 13:1227-1237.
15. McClay J.L., Adkins D.E., Aberg K., Stroup S., Perkins D.O., Vladimirov V.I., Lieberman J.A., Sullivan P.F., Van Den Oord E.J. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 2011, 16:76-85.
16. Need A.C., Keefe R.S., Ge D., Grossman I., Dickson S., McEvoy J.P., Goldstein D.B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 2009, 17:946-957.
17. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29:15-31.
18. Sullivan P.F., Lin D., Tzeng J.Y., Van Den Oord E., Perkins D., Stroup T.S., Wagner M., Lee S., Wright F.A., Zou F., Liu W., Downing A.M., Lieberman J., Close S.L. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol. Psychiatry 2008, 13:570-584.
19. Van Den Oord E.J., Adkins D.E., McClay J., Lieberman J., Sullivan P.F. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr. Res. 2009, 107:13-21.
20. Volpi S., Heaton C., Mack K., Hamilton J.B., Lannan R., Wolfgang C.D., Licamele L., Polymeropoulos M.H., Lavedan C. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 2009, 14:1024-1031.